Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms

摘要: Abstract Background Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use peptide as neoadjuvant agent resectable or potentially Methods postoperative outcomes 23 patients neoplasms at high risk recurrence who underwent (peptide group) were compared upfront surgical operation (upfront surgery group). Patients matched tumor size, grade, and stage. Median follow-up 61 months. Results size (median greatest width) primary decreased after (59 50 mm; P = .047). There no differences in intraoperative there operative deaths, but developing fistula tended be less group when (0/23 vs 4/23; P   .2) differed between groups, progression-free survival 31 had R0 resection seemed greater 15 versus 16 not reached 36 months; Conclusion Neoadjuvant high-risk features seems beneficial, well-designed much larger prospective trials are needed confirm safety oncologic value approach.